| CONTACT: |
| Supreme Court of the Philippines Library Services, Padre Faura, Ermita, Manila, Philippines 1000 |
| (632) 8524-2706 |
| libraryservices.sc@judiciary.gov.ph |
(NAR) VOL. 15 NOS. 3-4 / JULY / SEPTEMBER
[ BFAD BUREAU CIRCULAR NO. 14, S. 2004, October 12, 2004 ]
SUBMISSION OF ADVERSE DRUG REACTION REPORTS ON COX-2 INHIBITORS AS PART OF SAFETY MONITORING
The Bureau of Food and Drugs, after careful evaluation on the recent voluntary withdrawal of ROFECOXIB (VIOXX) from the Philippine market by its local company Merck Sharp & Dohme Philippines, has determined that all concerned pharmaceutical establishments with COX-2 inhibitors are required to monitor and submit adverse drug reaction reports on serious cardiovascular events including heart attacks and strokes.
Accordingly, the following COX-2 inhibitors shall be monitored and establishments should submit a monthly adverse drug reactions reports for 3 years:
For strict and immediate compliance.
Adopted: 12 Oct. 2004
(SGD.) PROF. LETICIA BARBARA B. GUTIERREZ, M.Sc.
Director
Accordingly, the following COX-2 inhibitors shall be monitored and establishments should submit a monthly adverse drug reactions reports for 3 years:
(1) Celecoxib
(2) Valdecoxib
(3) Meloxicam
(4) Etoricoxib
For strict and immediate compliance.
Adopted: 12 Oct. 2004
Director